Lv31
400 积分 2023-05-15 加入
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
2小时前
待确认
A novel dosing approach for rituximab in glomerular diseases based on a population pharmacokinetic analysis
11天前
已完结
Initial rituximab monotherapy for adult indiopathic nephrotic syndrome with minimal change lesion pattern
11天前
已完结
Studies of thermal injury; the predictability and the significance of thermally induced rate processes leading to irreversible epidermal injury
14天前
已关闭
Rituximab in primary membranous nephropathy: a comparative study of three dosing regimens
18天前
已完结
B-cell depletion in autoimmune diseases
18天前
已完结
Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy
22天前
已完结
Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy
25天前
已完结
Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up
1个月前
已完结
Introduction: Clinical Innovations in Onconephrology: What's New in 2023
3个月前
已关闭
皖公网安备34019202002308
